TAVR has transformed the treatment of aortic stenosis — procedural success rates are high, and early mortality has declined significantly. But procedural success doesn't guarantee post-discharge success.
Despite a successful valve replacement, a meaningful share of patients are readmitted within 90 days, and roughly two-thirds of deaths in this population are non-cardiac — driven by infection and systemic decline that standard care isn't built to catch.
The valve gets fixed. The patient doesn't automatically become invisible to risk. Synchronize Health's SYNC-PREVENT™ framework closes that gap by transitioning every TAVR patient into continuous Clinical Status Monitoring at discharge — not just the ones who already look high-risk.
The program layers hemodynamic monitoring with Vivio, arrhythmia surveillance with an ECG patch through the first month and then Kardia through day 90, heart failure detection through weight, blood pressure, heart rate, and SpO₂ trends, and continuous infection surveillance through the window where systemic decline does the most damage and gets watched the least.
Infection surveillance doesn't rely on temperature alone. Provider-ordered biomarker testing adds a second, independent signal for infection risk — using labs many patients are already having drawn, with no additional testing required.
Two independent signals for infection — continuous device-based temperature monitoring and provider-ordered biomarker testing — instead of relying on either one alone.
TAVR solves the valve. Synchronize Health extends visibility, reduces uncertainty, and enables earlier intervention — for everything after.